Table 5. Open in new tab Impact of...

Table 5.

Impact of Pre-IPV Type 2 Poliovirus Seroprotection Status on Stool Shedding Index After Oral mOPV2 Challenge, IPV001 and IPV002 Studies

Baseline Seroprotection Status^a	Subjects, No.	Shedding Index (95% CI)	P Value
IPV001
3 bOPV + 1 IPV dose
Positive	64	2.93 (2.20–3.50)	.28
Negative	187	2.38 (1.97–2.76)
3 bOPV + 2 IPV doses
Positive	105	2.05 (1.51–2.66)	.81
Negative	358	2.23 (1.89–2.37)
IPV002
1 IPV + 2 bOPV doses
Positive	98	3.98 (3.32–4.62)	.04
Negative	54	2.29 (1.65–3.81)
2 IPV + 1 bOPV dose
Positive	105	3.82 (2.85–4.62)	.002
Negative	63	2.62 (1.62–3.06)

Baseline Seroprotection Status^a	Subjects, No.	Shedding Index (95% CI)	P Value
IPV001
3 bOPV + 1 IPV dose
Positive	64	2.93 (2.20–3.50)	.28
Negative	187	2.38 (1.97–2.76)
3 bOPV + 2 IPV doses
Positive	105	2.05 (1.51–2.66)	.81
Negative	358	2.23 (1.89–2.37)
IPV002
1 IPV + 2 bOPV doses
Positive	98	3.98 (3.32–4.62)	.04
Negative	54	2.29 (1.65–3.81)
2 IPV + 1 bOPV dose
Positive	105	3.82 (2.85–4.62)	.002
Negative	63	2.62 (1.62–3.06)

Abbreviations: bOPV, bivalent oral polio vaccine; CI, confidence interval; mOPV2, monovalent oral polio vaccine, serotype 2; IPV, inactivated polio vaccine.

^aBaseline serologic status based on week 14 (IPV001) or week 8 (IPV002) serology.

This Feature Is Available To Subscribers Only